Loading company…
Pannex Therapeutics is developing drugs that block Pannexin 1 channels for several therapeutic areas.
Founded in 2020 and based in New York, US, Pannex Therapeutics is a preclinical biotechnology company developing drugs that block Pannexin 1 channels, a target associated with chronic pain. Its research covers potential applications in cardiovascular, inflammatory, pulmonary and central nervous system conditions. In October 2021, the company raised seed funding from SOSV.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in